FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Sean KhozinRichard Pazdur

Abstract

On April 29, 2014, the FDA granted accelerated approval to ceritinib (ZYKADIA; Novartis Pharmaceuticals Corporation), a breakthrough therapy-designated drug, for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. The approval was based on a single-arm multicenter trial enrolling 163 patients with metastatic ALK-positive NSCLC who had disease progression on (91%) or intolerance to crizotinib. Patients received ceritinib at a starting dose of 750 mg orally once daily. The objective response rate (ORR) by a blinded independent review committee was 44% (95% CI, 36-52), and the median duration of response (DOR) was 7.1 months. The ORR by investigator assessment was similar. Safety was evaluated in 255 patients. The most common adverse reactions and laboratory abnormalities included diarrhea (86%), nausea (80%), increased alanine transaminase (80%), increased aspartate transaminase (75%), vomiting (60%), increased glucose (49%), and increased lipase (28%). Although 74% of patients required at least one dose reduction or interruption due to adverse reactions, the discontinuation rate due to adverse reactions was...Continue Reading

References

Sep 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J B SørensenP Dombernowsky
Mar 18, 2008·Statistics in Medicine·Beat NeuenschwanderThomas Gsponer
Feb 1, 2011·The Lancet Oncology·William Pao, Nicolas Girard
Mar 23, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel B CostaKeith D Wilner
Jan 12, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Robert C DoebeleD Ross Camidge
Mar 9, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Giorgio ScagliottiJean-Charles Soria
Feb 13, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Geoffrey R OxnardPasi A Jänne
Jan 7, 2014·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Justin F GainorAlice T Shaw
Feb 28, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shakun M MalikRichard Pazdur
Mar 29, 2014·The New England Journal of Medicine·Alice T ShawJeffrey A Engelman
Mar 29, 2014·Cancer Discovery·Luc FribouletJeffrey A Engelman
May 3, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Christine M Lovly, Alice T Shaw
Jan 21, 2015·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Daniela IaconoLucio Crinò

❮ Previous
Next ❯

Citations

Nov 20, 2015·Expert Review of Clinical Pharmacology·Lorenza Landi, Federico Cappuzzo
Dec 15, 2015·Expert Review of Anticancer Therapy·Ittai B MullerGodefridus J Peters
Jan 14, 2016·The Lancet Oncology·Guo YuHong-Hao Zhou
Nov 11, 2015·Nature Reviews. Clinical Oncology·Kit Man WongS Gail Eckhardt
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Oct 31, 2015·Science·Baruch Fischhoff
Nov 29, 2015·Seminars in Oncology·Keara L RedmondSandra Van Schaeybroeck
Nov 26, 2015·ELife·Alex John London, Jonathan Kimmelman
Aug 12, 2015·Future Oncology·Anna S Berghoff, Matthias Preusser
Apr 1, 2016·Expert Review of Molecular Diagnostics·Esther CondeFernando Lopez-Rios
Aug 15, 2015·Journal of Clinical Pharmacology·Yvonne Y LauJeffrey Scott
Apr 26, 2016·Expert Review of Anticancer Therapy·Alessandro RussoVincenzo Adamo
Apr 29, 2016·Expert Opinion on Emerging Drugs·Janaki SharmaHaiying Cheng
Jul 1, 2016·Expert Opinion on Pharmacotherapy·Yi-Chen ZhangYi-Long Wu
Aug 9, 2016·BMC Cancer·Johanna S M MattssonMaria A Svensson
Aug 19, 2016·Expert Review of Anticancer Therapy·Giulio MetroRita Chiari
Aug 23, 2016·Clinical Pharmacology in Drug Development·Peter N MorcosAlex Phipps
Nov 5, 2016·International Journal of Pharmaceutics·Adam C FisherJanet Woodcock
Nov 2, 2016·Therapeutic Advances in Medical Oncology·Gustavo SchvartsmanErminia Massarelli
Mar 10, 2017·Expert Opinion on Drug Safety·Viola Zhu, S H Ou
Apr 13, 2017·Expert Review of Anticancer Therapy·Frédéric FiteniFranck Bonnetain
Aug 23, 2016·Clinical Pharmacology in Drug Development·Peter N MorcosAlex Phipps
Feb 16, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P S BoonstraM J Schipper
Oct 25, 2017·Pharmacogenomics·Nora S SánchezKenna R Mills Shaw
Jul 3, 2018·Future Medicinal Chemistry·Siming LiuJiajie Zhang
Aug 12, 2017·Circulation. Arrhythmia and Electrophysiology·Vitaly BuzaAnne B Curtis
Jan 17, 2019·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Danilo RoccoCesare Gridelli
Feb 17, 2018·Therapeutic Advances in Medical Oncology·Rodica Di Lorenzo, Manmeet S Ahluwalia
May 13, 2015·Nature Reviews. Clinical Oncology·Anish ThomasGiuseppe Giaccone
Jun 14, 2017·BMC Cancer·Qian ZhuJian-Chuan Xia
Apr 27, 2019·Journal of Hematology & Oncology·Chao ZhangWen-Zhao Zhong
Feb 22, 2018·Oncotarget·Marzia Del ReRomano Danesi
Oct 31, 2019·Journal of Diabetes Investigation·Haruka FujitaNobuya Inagaki

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.